Research programme: neuronal stem cell therapeutics - Samaritan/McGill University

Drug Profile

Research programme: neuronal stem cell therapeutics - Samaritan/McGill University

Alternative Names: SP-sc4; SP-sc7

Latest Information Update: 29 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Georgetown University; McGill University; Samaritan Pharmaceuticals
  • Developer CHDI; McGill University; Samaritan Pharmaceuticals
  • Class Small molecules; Stem cell factors
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease; Huntington's disease; Neurodegenerative disorders

Most Recent Events

  • 24 Jan 2008 The CHDI Foundation has non-exclusively licensed six compounds, including Sp sc4 and Sp sc7, for evaluation as potential therapeutics for Huntington's disease
  • 24 Jan 2008 Preclinical trials in Huntington's disease in USA (unspecified route)
  • 31 Jul 2007 Samaritan Pharmaceuticals has signed a research collaboration and licensing agreement with McGill University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top